MD Anderson Cancer Center Prostate Cancer SPORE

描述(申请人提供)：通过这项申请，德克萨斯大学MD安德森癌症中心寻求资金更新其前列腺癌孢子。本申请是由首席调查员Christopher J.Logothetis博士和Timothy C.Thompson博士根据多名首席调查员计划(MPI)提交的，他们在前列腺癌方面的研究在国际上享有盛誉。MD Anderson前列腺癌孢子为翻译研究创建了一个稳定和动态的基础设施，以满足并成功应对在降低前列腺癌男性患者痛苦和死亡率方面的具体挑战。我们继续加强进行新颖、创新的临床试验的能力，并相信由我们的翻译研究团队进行的新研究项目将在临床实践中产生实质性的进展和有意义的变化。在目前的提案中，我们将我们的翻译研究挑战和目标定义为：(1)前列腺癌风险的量化定义，以消除低风险前列腺癌的过度治疗，(2)开发新的治疗方法，以克服去势抵抗前列腺癌(CRPC)对现有治疗方法的耐药性，以及(3)为CRPC和治疗难治性疾病开发新的替代策略。我们将通过识别和测试新的预测和预后生物标记物来确定早期前列腺癌患者的治疗需求，开发和测试CRPC的新免疫疗法，开发和测试克服骨分泌介导的骨转移耐药的新方法，以及开发和测试引入联合疗法以最大限度地提高CRPC的DNA损伤反应靶向治疗，从而实现这些转译研究目标。我们将通过4个研究项目(包括1个人口科学研究项目)、3个支持核心(行政、生物统计学和生物信息学、生物谱学和病理学)、动态发展研究计划和有效的职业提升计划来实现我们的目标。我们乐观地认为，通过将基本研究成果转化为临床实践，我们的研究努力将有助于降低这种毁灭性疾病的发病率、发病率和死亡率。

DESCRIPTION (provided by applicant): Through this application, The University of Texas MD Anderson Cancer Center seeks funding for renewal of its Prostate Cancer SPORE. This application is submitted under the Multiple Principal Investigator plan (MPI) by Principal Investigators Drs. Christopher J. Logothetis and Timothy C. Thompson, who are recognized internationally for their research in prostate cancer, The MD Anderson Prostate Cancer SPORE has created a stable and dynamic infrastructure for translational research to meet and successfully address specific challenges in reducing suffering and mortality rates for men with prostate cancer. We continue to build on our capacity to conduct novel, innovative clinical trials and believe that new research projects conducted by our translational research team will yield substantial progress and meaningful changes in clinical practice. In the current proposal, we define our translational research challenges and goals as (1) quantitative definition of prostate cancer risk to eliminate overtreatment of low-risk prostate cancer, (2) development of novel therapeutic approaches to overcoming resistance of castration-resistant prostate cancer (CRPC) to available therapies, and (3) development of novel alternative strategies for CRPC and treatment-refractory disease. We will achieve these translational research goals by identifying and testing novel predictive and prognostic biomarkers to determine the need for therapy in patients with early-stage prostate cancer, developing and testing novel immunotherapy for CRPC, developing and testing a novel approach to overcoming osteocrine- mediated resistance of bone metastasis to therapy, and developing and testing lead-in combination therapy to maximize DNA damage response-targeted therapy for CRPC. We will accomplish our goals via 4 research projects (including one population science research project), 3 support cores (Administrative, Biostatistics and Bioinformatics, and Biospecimen and Pathology), a dynamic Developmental Research Program, and an effective Career Enhancement Program. We are optimistic that our research efforts will contribute to reductions in the incidence, morbidity, and mortality of this devastating disease by translating basic research findings into clinical practice.